Detalhe da pesquisa
1.
The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trials.
BJU Int
; 133(2): 158-168, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37422731
2.
Concomitant vs Staged Therapeutic Inguinal Lymphadenectomy in Clinically Node Positive Penile Squamous Cell Carcinoma: Does It Make a Difference?
J Urol
; 209(3): 557-564, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36652397
3.
Screening programs for renal cell carcinoma: a systematic review by the EAU young academic urologists renal cancer working group.
World J Urol
; 41(4): 929-940, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35362747
4.
Neglected lymph nodal metastases in patients with renal cancer: when to extend the anatomical template of lymph node dissection during nephrectomy.
World J Urol
; 41(6): 1573-1579, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37148324
5.
How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most?
World J Urol
; 40(11): 2667-2673, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36125505
6.
Patterns of Recurrence following Inguinal Lymph Node Dissection for Penile Cancer: Optimizing Surveillance Strategies.
J Urol
; 206(4): 960-969, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34032492
7.
The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something?
Int J Mol Sci
; 22(13)2021 Jul 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34281219
8.
Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with node-positive penile squamous cell carcinoma.
BJU Int
; 125(6): 867-875, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32175663
9.
A risk calculator predicting recurrence in lymph node metastatic penile cancer.
BJU Int
; 126(5): 577-585, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32662205
10.
Safe Use of Carfilzomib in a Patient with Multiple Myeloma and Intermittent Type 1 Brugada ECG Pattern: A Case Report.
Acta Haematol
; 143(5): 481-485, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31553985
11.
Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation.
Future Oncol
; 14(5): 443-448, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29318908
13.
Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review.
Eur Urol Oncol
; 7(1): 44-52, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37330413
14.
Preoperative risk calculator for the probability of completing nephron sparing for kidney cancer.
Urol Oncol
; 42(8): 247.e21-247.e27, 2024 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-38644109
15.
Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer.
Eur Urol
; 85(5): 417-421, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38184414
16.
Diagnostic Biopsy for Small Renal Tumours: A Survey of Current European Practice.
Eur Urol Open Sci
; 62: 54-60, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38585205
17.
The prognostic role of histomorphological subtyping in nonmetastatic papillary renal cell carcinoma after curative surgery: is subtype really irrelevant? A propensity score matching analysis of a multi-institutional real life data.
Urol Oncol
; 42(5): 163.e1-163.e13, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38443238
18.
Prognostic Significance of Grade Discrepancy Between Primary Tumor and Venous Thrombus in Nonmetastatic Clear-cell Renal Cell Carcinoma: Analysis of the REMEMBER Registry and Implications for Adjuvant Therapy.
Eur Urol Oncol
; 7(1): 112-121, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37468393
19.
Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs.
Res Rep Urol
; 15: 243-259, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37396015
20.
Systematic review of adoption, reporting and impact of health-related quality of life in phase III non-inferiority trials of systemic oncology treatments.
Eur J Cancer
; 195: 113374, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38557561